Evidence map›Paper›PMID 42918835›Full record

ReviewCommunications biology2026

Hepatitis E virus genome plasticity: a marker of chronicity and therapy failure?

Saskia Janshoff, Leyla Sirkinti, Maximilian K Nocke, Theresa S Bechtel, André Gömer, Yannick Brüggemann, Eike Steinmann, Richard J P Brown, Daniel Todt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saskia Janshoff *Ruhr University Bochum, Medical Faculty, Department of Translational and Computational Infection Research (TRACiR), Bochum, Germany.ORCID http://orcid.org/0009-0002-5675-674X
Leyla Sirkinti *Ruhr University Bochum, Medical Faculty, Department of Translational and Computational Infection Research (TRACiR), Bochum, Germany.
Maximilian K NockeRuhr University Bochum, Medical Faculty, Department of Translational and Computational Infection Research (TRACiR), Bochum, Germany.
Theresa S BechtelRuhr University Bochum, Medical Faculty, Department of Translational and Computational Infection Research (TRACiR), Bochum, Germany.
André GömerRuhr University Bochum, Medical Faculty, Department of Molecular und Medical Virology, Bochum, Germany.
Yannick BrüggemannRuhr University Bochum, Medical Faculty, Department of Molecular und Medical Virology, Bochum, Germany.
Eike SteinmannRuhr University Bochum, Medical Faculty, Department of Molecular und Medical Virology, Bochum, Germany.
Richard J P BrownRuhr University Bochum, Medical Faculty, Department of Translational and Computational Infection Research (TRACiR), Bochum, Germany. Richard.brown@ruhr-uni-bochum.de.ORCID http://orcid.org/0000-0002-3292-6671
Daniel TodtRuhr University Bochum, Medical Faculty, Department of Translational and Computational Infection Research (TRACiR), Bochum, Germany. Daniel.todt@ruhr-uni-bochum.de.ORCID http://orcid.org/0000-0002-3564-1014

Funding

Evaluating hepatitis E virus ribavirin resistance clinical outcomes in the immunosuppressed pig modelR21AI151736 · NIAID · OHIO STATE UNIVERSITY · PI JUNG, KWONIL, KENNEY, SCOTT P · 2021 to 2022
$410k
Deutsche Forschungsgemeinschaft (German Research Foundation) 499292334Deutsche Forschungsgemeinschaft (German Research Foundation) 510558817Deutsche Forschungsgemeinschaft (German Research Foundation) 518559083U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21AI151736
6 · The paper itself

Abstract

Hepatitis E virus (HEV) is a globally distributed zoonotic pathogen, spread by contaminated food and blood products, and a leading cause of acute viral hepatitis. Recent data indicate that the HEV genome contains a highly heterogeneous hypervariable region (HVR) that can tolerate extensive genomic rearrangements, especially among immunocompromised patients. These rearrangements can increase HEV replication in tissue-culture and have further been observed in HEV-infected patients. Insertions comprise either duplications of virus-derived sequences, or alternatively, host-derived sequence fragments and exhibit enrichment of specific amino acids and functional motifs. However, the molecular mechanisms driving these insertions, as well as their functional significance, remain largely unexplored. Given that sequences not required for infectivity or replication are typically rapidly eliminated in small RNA viruses such as HEV, the persistence of HVR insertions suggests a potential biological role in HEV replication and/or pathogenesis. This review summarizes our current understanding of the role of HVR insertions during HEV infection, as well as the potential mechanisms underlying these insertions. We further discuss the factors driving the selection of genomic insertions and speculate on their functional role by analyzing over 650 publicly available HEV genotype 3 genome sequences and systematically cataloging identified insertions.

Indexed as

Genome, ViralHepatitis EHepatitis E virusAnimalsHumansVirus Replication

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.